Astatine-211 based radionuclide therapy: Current clinical trial landscape

Astatine-211 ((211)At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Albertsson, Per, Bäck, Tom, Bergmark, Karin, Hallqvist, Andreas, Johansson, Mia, Aneheim, Emma, Lindegren, Sture, Timperanza, Chiara, Smerud, Knut, Palm, Stig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859440/
https://www.ncbi.nlm.nih.gov/pubmed/36687417
http://dx.doi.org/10.3389/fmed.2022.1076210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859440/
https://www.ncbi.nlm.nih.gov/pubmed/36687417
http://dx.doi.org/10.3389/fmed.2022.1076210

Ejemplares similares